Your browser doesn't support javascript.
loading
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
Abaza, Yasmin; Kantarjian, Hagop; Alwash, Yasmin; Borthakur, Gautam; Champlin, Richard; Kadia, Tapan; Garcia-Manero, Guillermo; Daver, Naval; Ravandi, Farhad; Verstovsek, Srdan; Burger, Jan; Estrov, Zeev; Ohanian, Maro; Lim, Miranda; Pemmaraju, Naveen; Jabbour, Elias; Cortes, Jorge.
Afiliación
  • Abaza Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Alwash Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Champlin R; Department of Stem Cell Transplant, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Verstovsek S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Burger J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Estrov Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lim M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cortes J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Am J Hematol ; 95(11): 1288-1295, 2020 11.
Article en En | MEDLINE | ID: mdl-32681739
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Protocolos de Quimioterapia Combinada Antineoplásica / Crisis Blástica Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Protocolos de Quimioterapia Combinada Antineoplásica / Crisis Blástica Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Año: 2020 Tipo del documento: Article